adcc 2014 2017 market report_201312
DESCRIPTION
2014-2017 Asia market projection of ADCC service (pre-clinical and GMP complied)TRANSCRIPT
![Page 1: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/1.jpg)
ADCC Market
Dec., 2013
![Page 2: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/2.jpg)
2
Outline
Mab/BioSimilar Market
ADCC Assay Brief
ADCC Service Market
![Page 3: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/3.jpg)
3
Biologics in BioPharma Market
Source: Evaluate Pharma, Sandoz analysis
By 2016, 7 of the top 10 pharmaceuticals worldwide will be biologics.
![Page 4: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/4.jpg)
4
Therapeutic mAbs drive BioPharma Market
![Page 5: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/5.jpg)
5
Current New mAbs Pipeline
In total, > 574 mAbs
![Page 6: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/6.jpg)
6
Global BioSimilars Market Scenario
Source: 2013 Annual Reports, SEC Filings, Market Analysis
![Page 7: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/7.jpg)
7
Top Reference Products with BioSimilars in Development 2013
*As of July,2013
Source: PhRMA reports
![Page 8: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/8.jpg)
8
Current BioSimilars Pipeline
As of June 2013, including 514 candidate biosimilars and 402 biobetters, a total of 916 products in development concerning >140 mabs and proteins that are currently approved in the United States.
Source: BII pipeline database
![Page 9: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/9.jpg)
9
***Geographic distribution of companies
**Geographic distribution of products by company *Companies with largest biosimilar portfolios
*As of June,2013Source: BII pipeline database
Current BioSimilars Pipeline
![Page 10: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/10.jpg)
10
# of mAbs/biosimilars in 2015
Biosimilars launched date: In 2015, around 55 on market
Approved mAb drugs on the market:So far, total 53, around 58 in 2015
Source: SameDan Ltd, Winter 2012
![Page 11: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/11.jpg)
11
Bioassay/ADCC Required in Regulation
Fingerprint mAbs/fusion proteins as ICH, US-FDA, EMA etc. recommend.
![Page 12: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/12.jpg)
12
Mechanism of Action (MOA) for mAb
Nature Review. Drug Discovery. Volume 10, Feb 2011-101
![Page 13: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/13.jpg)
13
What is ADCC?
![Page 14: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/14.jpg)
14
When is ADCC needed?
Starting from phase I and even earlier, ADCC assay should be performed for biologics potency assessment.
![Page 15: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/15.jpg)
15
What is ADCC for?
MAbs/Biosimilars/Biobetters discovery research High-throughput screening Characterization and process development of therapeutic molecules Batch/lot or quality control release testing of clinical product Stability testing In-vitro detection of neutralizing antibodies If significant changes to process, facility transfers, line-extensions
![Page 16: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/16.jpg)
16
Classic ADCC Assays
![Page 17: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/17.jpg)
17
Major Players in ADCC Assay
![Page 18: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/18.jpg)
18
ADCC Market Prediction
Current ADCC assay in industry: $16K -- $25K, averagely $20K per assay
Scenario 1 – mAbs/biosimilar pre-approval
Averagely, at least 10 times of ADCC assay for one candidate each yearCurrently, # of new mAb entities in pipeline is > 514, # of biosimilars/biobetters in pipeline is around 916.25% of pipeline is in Japan/Korea/China.
Market size: (514+916)*10*$20K *25%= $71.5M
![Page 19: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/19.jpg)
19
ADCC Market Prediction
Scenario 2 – mAbs/biosimilar manufacturing Post-Approval
2-1. The manufacturing volume reaches to 5*10^7 L in Korea/China in 2015. 500L-20,000L/bioreactor, averagely 10,000L/batch.
Market size in Korea/China: 5*10^7/10,000*$20K = $100M
2-2. Revenue of mAbs drug in 2015 is around $86B globally. 5% of cost for QC. 2% of QC cost for ADCC. 70% of mAbs manufactured in Korea/China.
Market size in Korea/China: $86B*5%*5%*70% = $60M
![Page 20: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/20.jpg)
20
ADCC Market Prediction
Scenario 2 – mAbs/biosimilar manufacturing Post-Approval
2-3. Averagely, 1 time of ADCC assay per drug per week. Totally around 113 mAbs/ biosimilars on the market in 2015. 70% of biologics manufactured in Korea/China.
Market size in Korea/China: 113*1*52*70%*$20K = $83M
Totally, $71.5M + ($100M+$60M+$83M)/3 = $152.5M
ADCC Service Contact: cn.linkedin.com/in/jasonsoung/
![Page 21: ADCC 2014 2017 market report_201312](https://reader036.vdocuments.mx/reader036/viewer/2022062419/55794bb9d8b42a31678b50c7/html5/thumbnails/21.jpg)
21
Move together, Win together.